Illumina Q3 earnings beat estimates, prompting Cwm LLC to boost its stake by 43.9%. Discover why analysts maintain a 'Hold' ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Learn more about whether Charles River Laboratories International, Inc. or Illumina, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics ...

The First Trust Large Cap Core AlphaDEX ETF (FEX) made its debut on 05/08/2007, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Blend category of the ...

Tempus AI’s TEM reimbursement showed modest sequential improvement in the third quarter of 2025, though average blended ...

Commissioner Scott Gottlieb expressed concern over the Trump administration’s pending overhaul of the childhood vaccine ...

According to MarketsandMarkets™, The report Single-molecule Real-time (SMRT) Sequencing Market is projected to grow from USD ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Illumina (ILMN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in ...

Illumina (NASDAQ:ILMN) supports global genomic science as nasdaq futures discussions include advanced life sciences platforms ...

In a report released today, Michael Ryskin from Bank of America Securities reiterated a Hold rating on Tempus AI, Inc. Class A, with a price target of $80.00.

According to Mordor Intelligence, the healthcare IT market is valued at USD 413.14 billion in 2025, and is projected to surpass USD 839.67 billion by 2030, at a CAGR of 15.24% during the forecast ...